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DifferentiatingMuscleDamage fromMyocardialInjuryby Means of the
SerumCreatineKinase(CK) lsoenzymeMB Mass Measurement’TotalCK
ActivityRatio
Magdeielne El Allaf,1Jean-Paul Chapeiie,1’#{176}Dia El Aliaf,2 Albert Adam,3 Marle-Elisabeth Faymonvllie,4
Philippe Laurent,5 and Camille Heusghem1
We immunoenzymometricallymeasured creatine kinase
(CK) isoenzyme MB in extracts of myocardium and in ho-
mogenatesof fivedifferentskeletalmuscles.CK-MB concen-
trationsin the former averaged 80.9 jg/g wet tissue; in the
skeletalmusclesit varied widely, being(e.g.) 25-foldgreater
in diaphragm than in psoas. CK-MB in skeletal muscles
ranged from 0.9 to 44 ng/U of total CK; the mean for
myocardiumwas 202 ng/U. In sera from 10 trauma and 36
bum patients without myocardial involvement, maximum
ratios for CK-MB mass/totalCK activity averaged 7 (SEM 1)
ng/U and 18 (SEM 6) ng/U, respectively.Exceptforan infant
(220 ng/U), the highest ratio we found for serum after
muscular damage was 38 ng/U. In contrast, the mean
maximumratio determinedin 23 cases of acute myocardial
infarction exceeded 200 ngJU. Amongseven determinations
performed 8 to 32 h afteronsetof symptoms,eachinfarct
patientdemonstratedat least one ratio 110 ng/U. Ratios
observed after infarctwere unrelated to treatment received
during the acute phase.We propose a CK-MB/total CK ratio
of 80 ng/U as the cutoffvalue for differentiatingmyocardial
necrosisfrom muscular injury.
AdditionalKeyphrases:acute myocardialinfarction immuno-
enzymometnc assay enzyme mass vs catalytic activity
The major clinical application of assay of the MB isoen-
zyme of creatine kinase (CK, EC 2.7.3.2) in serum is to
assess the possibility and extent of acute myocardial infarc-
tion (AMI) or, more broadly, to differentiate myocardial
injury from skeletal muscle damage. The ratio of CK.MB to
CK-MM isoenzyme is markedly higher in myocardiuni than
in skeletal muscles, and CK-MB activities in serum are
generally considered as indicative of AM! when they exceed
3 to 5% of total CK activity (1, 2).
In some studies, however, proportions of CK-MB have
exceeded 6% in serum of subjects with multiple trauma or
severe burns but without apparent myocardial injury. These
unexpectedly high CK-MB contents in skeletal muscles
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have called into question the efficiency of assay of this
isoenzyme for diagnosing AM! in patients with muscular
damage (3,4). Moreover, analytical methods measuring the
catalytic activity of CK-MB have produced conflicting re-
sults as to the proportions of the CK isoenzymes in the
human tissues (5, 6). Thus we have used a new immunoen-
zymometric assay, designed to determine the mass concen-
tration of CK-MB with improved specificity (7), to reexam-
ine the CK-MB content of skeletal and heart muscles. We
have also applied this technique to serum specimens taken
serially from patients with multiple trauma, burns, or AM!,
to appraise the patterns of CK-MB release into the blood
and to assess the magnitude of the changes in the serum
concentration of this isoenzyme after muscle and myocardi-
urn damage. Finally, we wanted to investigate the value of
CK-MB mass measurements for the differential diagnosis of
AM! and skeletal muscle injury.
Materials and Methods
Patients
We studied three distinct categories of patients, from
whom blood samples were taken serially during their hospi-
tal stay:
.10 trauma patients (nine men and one woman, mean age
40, SD 18 years) admitted with multiple fractures after
motor-vehicle accidents. Criteria of selection of subjects for
the study were short delays before hospitalization (<75 mm)
and absence of any clinical evidence of myocardial necrosis
or ischemia. Blood was sampled on admission and every 6 h
during the following two days.
.36 burn patients (20 males and 16 females-including
two children, one- and 17-months old-mean age 24, SD 19
years). Myocardial involvement was also ruled out in all
these patients, but the intervals before hospitalization were
less uniform than was the case for the trauma patients (0.5-
7.5 h, mean 3.5, SD 2.9 h). Blood was sampled upon
admission and 24 and 48 h later. The Burn Unit Skin (BUS)
classification was used to rate the severity of burns (8). The
BUS score was <100% for 21 of these patients, between 100
and 150% for nine, and >150% for six. Seventeen patients
survived without complication, 14 survived but contracted
septicemia, and five died within six days.
.23 AM! patients (17 men and six women, mean age 58,
SD 9 years) who were admitted to the Coronary Care Unit
(CCU) comprised the third category of patients. AM! was
diagnosed on the basis of a typical clinical history, electro-
cardiographic evidence, and the characteristic increase and
decrease of total CK activity in serum. To be included in the
study, patients had to reach the CCU within 4 h after the
onsetofchestpain and initial CKvalueshadtobe lessthan
150 UIL. Eleven patients received fibrinolytic therapy (in-
tracoronary perfusion of 0.8-1.0 x iO units of streptokinase
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within 30 mm) within 15 mm of admission, whereas the
other 12 patients were treated in a more conventional
manner (administration of continuous intravenous heparin,
1000 units/h). For all these patients, blood was sampled
upon admission, every 4 h during the first 36 h, and every 12
h thereafter until 72 h.
Tissue Homogenates
From specimens of muscle (diaphragm, psoas, pectoralis
major, intercostal, femoralis) and myocardium tissue taken
at autopsy within 6 h after death from three different
subjects, homogenates were prepared as previously de-
scribed (9). In brief: precisely weighed muscle and myocardi-
urn fragments (about 1 g) were homogenized in ice-cold pH
7.0 Tris acetate buffer in an Ultra-Turrax blender. Cell
fragments were removed by centrifugation at 4000 x g. The
supernates, kept on ice, were analyzed the same day for
total CK activity and CK-MB mass.
Biochemical Constituents
Total CK. Total CK activities in serum (reference inter-
val: 0-100 UIL) were determined at 37#{176}Cwith an optimized
spectrophotometric method (CK UV test, no. 3388; Merck,
Darmstadt, F.R.G.) according to Rosalki (10), by using a
discrete analyzer (ABA 100; Abbott Labs., North Chicago,
IL 60064). The linearity limit was 1500 U/L. Dilutions were
made in heat-inactivated serum, in the ratio 1:10 or, excep-
tionally, 1:100. In contrast to isotonic saline, heat-inactivat-
ed serum has no “activity” effect on CK (11).
CK-MB
CK-MB. We measured CK-MB concentrations with a
solid-phase, two-site immunoenzymometric assay (Tandem-
E CKMB; Hybritech Europe S.A., Sart Tihnan, Liege,
Belgium), using the Hybritech ‘Photon” photometer (7). In
this technique, samples containing CK-MB are reacted with
a plastic-bead solid phase that is coated with a monoclonal
antibody directed toward the M subunit of CK-MB, and with
an enzyme-labeled monoclonal antibody directed toward the
B subunit of the molecule. After the formation of the solid
phase/CK-MB/labeled-antibody “sandwich”, the bead is
washed, then incubated with enzyme substrate (p-nitro-
phenyl phosphate). The amount of substrate turnover, deter-
mined colorimetrically, is directly proportional to the con-
centration of CK-MB in the test sample. All measurements
were done in duplicate. The mass concentrations of CK-MB
(g/L) were numerically about double the activities (UIL)
obtained with the immunoinhibition method at 37#{176}C(CK-
MB UV test, Merck) (12).
Sample Stability
The serum samples collected in the three participating
centers (Centre des Br#{252}l#{233}sat Lyon and CCU and Depart-
ment of Surgery, Liege) were stored at -22 #{176}Cand trans-
ferred within 15 days to the Laboratory of Clinical Chemis-
try of the University of Liege. Total CK activity and CK-MB
mass were measured immediately after thawing. Total CK
activity is stable during storage at -22 #{176}C(13). We did not
find any statistical differences in the CK-MB mass concen-
trations measured before and after storage at -22 #{176}C(10
replicates) during 30 days for three serum pools with
increasing CK-MB content (17,54, and 152 g/L). Moreover,
seven successive freezings and thawings of these specimens
at approximately 12-h intervals only lowered the CK-MB
mass concentration by 5%.
Results
Patternsof Total CK and CK-MB Release after
injuriesto Muscle and Myocardium
Patients with multiple trauma. In the 10 trauma patients,
total CK activities in serum markedly increased during the
first day of hospitalization and the peak value (mean 15588,
SEM 7648 U/L) was recorded after 30 h (Table 1).
The mean curve for CK-MB mass concentrations peaked
after 18 h (20.6, SEM 7.7 gfL). CK-MB decreased during
the second day after trauma and, in contrast to total CK
activities, had nearly become normal after 48 h (Figure IA).
The highest values for the nine CK-MB mass concentrations
measured in each patient ranged from 5.5 to 67.1 ,ug/L
(mean 21.4, SEM 7.6 ig/L). Regularly decreasing values
were obtained for the CK-MB mass/total CK activity ratio
during the period of investigation (Figure IB). Mayimum
ratios averaged 7 (SEM 1) ng/U (range 2-13 ngfU).
Patients with burns. In the serum of the 36 burn patients,
mean total CK activities regularly increased during the first
two days of hospitalization (Table 1). In contrast, close mean
values about 7 1zg/L were obtained for CK-MB mass concen-
trations. The highest of the three individual values obtained
for CK-MB ranged from 0.1 to 69.0 ug/L (mean 11.7, SEM
3.0 g/L). Because of lower total CK activities, the CK-MB
mass/total CK activity ratios were, however, greater than in
the trauma patients at the corresponding measurement
times. Maximum ratios averaged 18 (SEM 6) ng/tJ. In our
series, only the one-month-old child demonstrated CK-MB
mass/total CK ratios >40 ng/IJ: 220 ngfU upon admission
(total CK 76 U/L, CK-MB 16.7 ug/L), 90 ng/tJ (total CK 185
U/L, CK-MB 16.6 gIL) after 24 h, and 63 ng/LJ (total CK
125 UIL, CK-MB 7.9 ug/L) after 48 h. In the 35 remaining
Table 1. Total CK ActIvItIes and CK-MB Mass Concentrations In Patients with MultipleTrauma,Burns,and AMI
(Conventional Treatment), at AdmIssIon and 24 and 48 h Later
MultIpi. trauma Bums AMI
Adm 24 h 48 h Mm 24 h 48 h Mm 24 h 48 H
Total CK activity, UIL
X±SEM 349±127 13274±6280 14028±6076 1284±372 1840±684 2711±1502 105±18 1283±272 511±99
Range 8-1090 1240-52500 1400-52000 42-8650 19-19000 15-49200 50-260 343-2990 116-1220
CK-MB concentration, pg/L
X±SEM 1.7±1.2 17.4±6.3 3.3±1.7 7.7±2.4 6.9±2.1 6.8±2.4 2.6±0.9 164.5±30.3 23.9±6.3
Range 0-9.6 3.6-54.4 0.4-14.1 0-69.0 0-61.7 0-64.3 0-8.7 37.3-314.0 0.4-64.2
CK-MB mass/total CK activity ng/U
X±SEM 4±2 3±1 0.2±0.1 17±7 9±3 7±2 25±98 164±29 32±9
Range 0-13 1-4 0.1-0.3 0-220 0-90 0-63 0-72 65-371 11-72
A B
BUS score. S
<100
(n = 20)
CK-MB concentration, jtg/L
AdmIssion 6.0 ± 4.4
24h 3.3±1.9
48h 2.0±0.7
CK-MB mass/total CK activity, ngIU
Admission 11 ± 3
24h 6 ±2
48h 5 ±2
100-150
(n 9)
4.4 ± 2.9
7.0 ± 3.1
7.9 ± 4.5
3 ±1
8 ±4
5 ±2
aResuts for the one-month-old infant excluded from this group.
Maximum
values Peak
Return to
normal
Maximum
value Peak
15.0±1.9
13.0±1.8
Return to
normal
55.5±1.9
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FIg. 1. Compansonofthemean(±SD) seiumCK-MBconcentrations
(lefi)orofthemean (± SD)CK-MB/totalCKratios (right)ui patients with
multiple trauma (-, n = 10) andinpatientswithAMI,treatedwith
hepatin (-, n = 12)or by Intracoronary perfusion with streptoidnase
(_._ = 11)
patients, the maximum ratios averaged 11 (SEM 2) ngfU
(range 1-38 ng/tJ).
The patient population was subdivided into three differ-
ent categories according to the BUS score (8) calculated for
each patient (Table 2). While constantly decreasing in the
20 subjects with the lowest BUS values (<100%), the CK-
MB mass concentrations regularly increased during the first
48 h of hospitalization in the patients with the most severe
burns. The most important differences in CK-MB values
among the three groups of burn patients were recorded at
the end of day 2 (F = 3.6,p <0.05). The CK-MB mass/total
CK activity ratios were not related to burn severity.
AMI patients. Serum total CK activities and CK-MB mass
concentrations peaked earlier (p <0.05) in the streptoki-
nase-treated subjects than in the patients who received
intravenous heparin (Table 3). There was, however, no
statistical difference between the maximum values recorded
Table 2. Serum CK-MB Mass Concentrations (X ±
SEM) Recorded at Admission and 24 and 48 h Later for
the Bum Patients, Classified AccordIng to Severity of
the Bums
in the two groups. The highest of the seven values obtained
for CK-MB mass concentrations between 4 and 28 h after
hospital admission in the streptokinase- and heparin-treat-
ed group ranged from 85 to 693 .tg/L and from 115 to 635
g/L, respectively. The evolution of the CK-MB mass/total
CK ratios in the course of AM! was also independent of
treatment (Figure 1B). During the corresponding 24-h peri-
od, the individual maximum ratios averaged 230 ng/U
(range 110-460 ng/U) in the patients who received a fibrino-
lytic therapy and 220 ng/IJ (range 120-400 ngfU) in the
subjects treated with heparin.
Total CK Activityand CK-MB Mass Concentrationin
Tissue Homogenates
Total CK activity and CK-MB mass concentration were
determined in homogenates prepared from myocardium and
skeletal muscle (psoas, pectoralis major, diaphragm, femor-
alis, and intercostal) specimens obtained at autopsy.
In skeletal muscles, the CK-MB mass concentrations
ranged from 0.8 (psoas) to 21.4 tg (diaphragm) per gram
(wet weight) of tissue (Table 4), and the CK-MB mass/total
CK activity ratio from 0.9 (paces) to 44 ng/IJ (diaphragm).
One gram of myocardium contained, on average, 80.9 ,ug of
CK-MB, and the mean CK-MB/total CK ratio was 202 ng/U.
DIscussion
Determination of the CK-MB content of skeletal muscles
has led to conflicting results (14). Some authors reported
CK-MB activities >20% of total CK (15,16); others failed to
demonstrate CK-MB in the muscular tissue (17). Various
drawbacks of the analytical methods used to measureCK-
MB activities are probably partly responsible for these
discordances. Electrophoresis is known to overestimate CK-
MB (18); mitochondrial CK, macro-CK, and adenylate ki-
nase (EC 2.7.4.3) interfere with the chromatographic and
immunoinhibition assays (19-21). Hence, after correcting
for residual adenylate kinase the MB activities measured by
immunoinhibition in skeletal muscle homogenates, Urdal et
al. (22) found that the contribution of CK-MB to the total
CK activity was only 1.1%.
Quantitative differences in the CK isoenzyme pattern
from one muscle to another are also sources of divergence
_______between results. In 1965, Eosalki (23) noted that the CK-
MB content of the human skeletal muscles could vary in
=6) relation to the proportion of fibres of type land II. Tsung (24)
observed large differences in the CK-MB proportions of
1.2 ± 0.3 different skeletal muscles. Bentz et al. (25) found that the
17.1 ± 8.6 CK-MB activity represented 0.1% of the total CK in rectus
21.4 ± 10.7 abdominus and 4.2% in diaphragm. Recently, Sylven et al.
reported a positive correlation between CK-MB and the
8 ± percentageoftypelfibresinthemuscle(26).
Our use of’ the “Tandem-E CKMB” assay allowed us to
demonstrate that the differences in the CK-MB content of
the human skeletal muscle were greater than usually
Table 3. CharacterIstic of Total CK and CK-MB (Mean ± SEM) Release In the Streptokinase Treated and Non-
Treated AMI Patients
H.p.rln treatment (n = 12) Strsptoklnaa. fibrinolysis (n = 11)
Time, h Time, h
TotalCKactivity 1486±281 U/L 20.4±2.2 1608±429 U/L
CK-MB concentration 270.4±45.5 ig/L 16.7±2.0 60.0±3.6 298.8±57.8 Lg/L
Pectoralls
Myocardlum Picas Diaphragm F.moralls major lntercos
881 938 1051 883
433 851 870 689
370 773 944 784
561 854 955 819
Total CK activity, Uig
406 602
350 925
- 438 1064
X 398 864
CK-MB concentration, g/g
93.7 0.3 18.0 3.5 12.5 5.3
63.0 0.6 34.0 4.9 7.3 0.9
- 85.9 1.6 12.3 3.1 9.5 2.1
X 80.9 0.8 21.4 3.8 9.8 2.8
CK-MB mass/total CK activity, ng/U
231 0.5 20 4 12 5
180 0.6 79 6 8 1
- 196 1.5 33 4 10 3
X 202 0.9 44 5 10 3
Table 4. ActIvity of Total CK and Mass Concentration of CK-MB In Human Myocardlum and Skeletal Muscles
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reported: the concentration of CK-MB per gram of wet tissue
was, for example, 24-fold greater in diaphragm than in
psoas. We also showed that the CK-MB content of the
myocardium was only four-fold that in diaphragm. Howev-
er, due to the fact that total CK activities per gram of tissue
were higher in skeletal muscles than in myocardium, the
differences in the CK-MB mass/total CK activity ratios were
more important: for four of the five skeletal muscles we
investigated, the CK-MB mass/total CK activity ratio (10
ng/U) was more than 20-fold lower than that for myocardi-
urn (202 ng/U).
Published results also differ concerning serum CK-MB
concentrations after muscle injury. In polytrauma patients
without myocardial involvement, OK-MB activities report-
edly ranged from 0 to 5.7% (27) or were about 1% of total CK
(28). The CK-MB activities in serum of patients with
electrical burns, thermal burns, and blunt trauma averaged
8.6,4.6, and 5.7% of total CK, respectively, with an overall
range of 0.5 to 22% (4).
In this work, we studied the dynamics of the CK-MB
release in the blood after muscular injury. lmmunoenzymo-
metric measurements performed at 6-h intervals after ad-
mission in the trauma patients indicated an increase and
decrease of CK-MB mass concentrations (Figure IA), with
maximum values 18 h after admission. In the patients with
the most severe burns, CK-MB peaked later (48 h) but the
maximum concentration (mean 21.4 pg/L) was very dose to
that calculated for the trauma patients (mean 20.6 ‘L).
Similarly, there was excellent agreement between the
ranges of maximum CK-MB concentrations in the trauma
patients (5.5 to 67.1 ig/L) and in the burn patients (0.1 to
69.0 ig/L). There was also little difference between the
maximum CK-MB mass/total CK activity ratios recorded
for these two groups: 2 to 13 ng/U (mean 7) in the trauma
patients and 1 to 38 ngfIJ (mean 11) in the burn patients,
after exclusion of results for the one-month-old infant. The
high ratios (63 to 220 ng/U) found in the latter are likely to
be related to an increased CK-MB fraction during develop-
ment of the human muscle (29).
The excellent agreement between the range of the CK-
MB mass/total CK ratios in muscle tissue (0.9-44 ng/U) and
the range of the maximum serum ratios measured after
muscle injury (1-38 ng/U) in the overall population of
trauma and burn patients must also be emphasized. The
same holds true for the CK-MB mass/total CK activity
ratios determined in myocardium specimens and in the sara
of AMI patients.
Early intracoronary perfusions with streptokinase are
now widely used in AM! patients who reach the CCU
shortly after the attack, in order to recanalize the obstructed
coronary artery and, consequently, to limit the infarcted
area (30). Successful fibrinolytic therapy is known to modify
the kinetics of enzyme release, because the increased wash-
ing-out from the ischemic area leads to an earlier appear-
ance of the tissue markers in the patients plasma (31,32).
Although serum total CK activity and CK-MB mass concen-
trations peaked earlier in the patients treated with strepto-
kinase than in those who received heparin (Table 3), the
treatment had no influence on the magnitude of the changes
of CK-MB concentrations and on the evolution of
the OK-MB mass/total CK activity ratios (Figure 1B) in the
course of the disease. The maximum serum CK-MB concen-
trations recorded during the 4th and the 28th hours after
admission-that is, given the delays in hospitalization,
about 8 to 32 h after the onset of chest pain-ranged from
115 to 635 ug/L in the patients with conventional treatment
and 85-693 pgfL in those who received fibrinolytic therapy.
During this 24-h period, the patients of these two groups
demonstrated at least one CK-MB mass/total CK activity
ratio 110 ng/U.
The use of two monoclonal antibodies, directed towards
the M and B subunits of the CK-MB molecule, makes the
Tandem method highly specific. As previously demonstrat-
ed (12), large excess of CK-MM and of CK-BB did not
interfere with the assay, confirming the results obtained by
others with a two-site immunoradiometric assay (33). The
fact that no modification of the CK-MB results were ob-
served after addition of hemolysates up to a final hemoglo-
bin concentration of 1.5 g/L (12) also indicated that adenyl-
ate kinase does ot influence the Tandem assay. Thus, the
immunoenzymometric assay does not require dilution of the
sample when CK-MM is present in large quantities; more-
over, it yields reliable results in the presence of adenylate
kinase originating from muscles or erythrocytes. The excel-
lent stability of the CK-MB molecule at -22 #{176}Cis an
additional advantage of mass measurements over catalytic
activity determination.
Conclusion
We previously determined the reference range for CK-MB
mass concentrations in presumably healthy subjects to be 0-
6 g/L (12). These values were close to those (0-4 g/L)
established in normal individuals by Chan et al. (7), who
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recommended, however, use of a broader reference interval
(0-9 zg/L) for non-infarct patients. Our study demonstrates
that in fact CK-MB mass concentrations as great as 69 1tgfL
may be present in serum of patients with skeletal muscle
injury, and therefore that a cutoff value of 9 ug/L would
lead, in trauma patients, to numerous false indications of
AMI. We propose, therefore, that the assessment of myocar-
dial necrosis be based on the serum CK-MB mass/total CK
activity ratio rather than on the absolute concentration.
None of the trauma or burn patients older than one year
demonstrated a CK-MB mass/total OK activity ratio >40
ng/U at any time during the first 48 h following the
accident. Thus we chose the value of 80 ng/IJ-twofold the
maximum ratio recorded in the patients with muscular
injury-as cutoff for differentiating skeletal muscle and
myocardiuni necrosis. When several CK-MB mass measure-
ments were performed between 8 and 32 h after the onset of
the symptoms, all AMI patients demonstrated at least one
value 110 ng/U for the CK-MB mass/total OK activity
ratio whether or not they had received fibrinolytic therapy.
Consequently, use of the cutoff value of 80 ngfU will
completely differentiate AMI patients from those with trau-
ma or burns, thus allowing detection of myocardial necrosis
even in the presence of pre-existing muscular damage.
We are indebted to Mrs. M-C. Aldenhoff and N. Heiligers for their
technical assistance, and to Mrs. B. Cornet for help in the prepara-
tion of the manuscript.
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